Table 1. Patient demographics and clinical characteristics by practice type and asthma severity in the Malaysian cohort of SABINA III.
|
|
Primary care (n=265) |
Specialty care (n=466) |
Total (N=732)* |
||||
|---|---|---|---|---|---|---|---|
|
|
Mild asthma (n=180) |
Moderate-to-severe asthma (n=85) |
All (n=265) |
Mild asthma (n=73) |
Moderate-to-severe asthma (n=393) |
All (n=466) |
|
|
Age, year, mean (SD) |
49.77 (13.96) |
54.74 (14.27) |
51.36 (14.23) |
49.33 (16.24) |
50.96 (15.31) |
50.71 (15.45) |
50.93 (15.01) |
|
Women, n (%) |
144 (80.0) |
64 (75.3) |
208 (78.5) |
55 (75.3) |
319 (81.2) |
374 (80.3) |
583 (79.6) |
|
Men, n (%) |
36 (20.0) |
21 (24.7) |
57 (21.5) |
18 (24.7) |
74 (18.8) |
92 (19.7) |
149 (20.4) |
|
BMI, kg/m2, mean (SD) |
28.19 (5.95) |
29.63 (6.9) |
28.65 (6.3) |
28.58 (7.74) |
28.74 (6.25) |
28.72 (6.5) |
28.69 (6.42) |
|
25-29.9, n (%) |
61 (33.9) |
25 (29.4) |
86 (32.5) |
26 (35.6) |
127 (32.3) |
153 (32.8) |
240 (32.8) |
|
>30, n (%) |
62 (34.4) |
37 (43.5) |
99 (37.4) |
24 (32.9) |
151 (38.4) |
175 (37.6) |
274 (37.4) |
|
Smoking status | |||||||
|
Active smoker |
6 (3.3) |
0 (0.0) |
6 (2.3) |
2 (2.7) |
4 (1.0) |
6 (1.3) |
12 (1.6) |
|
Former smoker |
11 (6.1) |
8 (9.4) |
19 (7.2) |
5 (6.8) |
25 (6.4) |
30 (6.4) |
49 (6.7) |
|
Never smoker |
163 (90.6) |
77 (90.6) |
240 (90.6) |
66 (90.4) |
364 (92.6) |
430 (92.3) |
671 (91.7) |
|
Educational level | |||||||
|
Primary school |
25 (13.9) |
14 (16.5) |
39 (14.7) |
3 (4.1) |
51 (13.0) |
54 (11.6) |
93 (12.7) |
|
Secondary school |
103 (57.2) |
50 (58.8) |
153 (57.7) |
39 (53.4) |
159 (40.5) |
198 (42.5) |
352 (48.1) |
|
High school |
22 (12.2) |
10 (11.8) |
32 (12.1) |
9 (12.3) |
34 (8.7) |
43 (9.2) |
75 (10.2) |
|
University or higher |
26 (14.4) |
11 (12.9) |
37 (14.0) |
20 (27.4) |
132 (33.6) |
152 (32.6) |
189 (25.8) |
|
Unknown |
4 (2.2) |
0 (0.0) |
4 (1.5) |
2 (2.7) |
17 (4.3) |
19 (4.1) |
23 (3.1) |
|
Healthcare insurance or medical funding | |||||||
|
Not reimbursed |
0 (0.0) |
0 (0.0) |
0 (0.0) |
3 (4.1) |
35 (8.9) |
38 (8.2) |
38 (5.2) |
|
Partially reimbursed |
0 (0.0) |
0 (0.0) |
0 (0.0) |
7 (9.6) |
19 (4.8) |
26 (5.6) |
26 (3.6) |
|
Fully reimbursed |
180 (100.0) |
85 (100.0) |
265 (100.0) |
60 (82.2) |
339 (86.3) |
399 (85.6) |
665 (90.8) |
|
Unknown |
0 (0.0) |
0 (0.0) |
0 (0.0) |
3 (4.1) |
0 (0.0) |
3 (0.6) |
3 (0.4) |
|
Comorbidities | |||||||
|
None |
43 (23.9) |
10 (11.8) |
53 (20.0) |
25 (34.2) |
98 (24.9) |
123 (26.4) |
177 (24.2) |
|
1-2 |
100 (55.6) |
36 (42.4) |
136 (51.3) |
37 (50.7) |
192 (48.9) |
229 (49.1) |
365 (49.9) |
|
3-4 |
36 (20.0) |
30 (35.3) |
66 (24.9) |
11 (15.1) |
82 (20.9) |
93 (20.0) |
159 (21.7) |
|
≥5 |
1 (0.6) |
9 (10.6) |
10 (3.8) |
0 (0.0) |
21 (5.3) |
21 (4.5) |
31 (4.2) |
BMI, body mass index; SABA, short-acting ß2-agonist; SABINA, SABA use IN Asthma; SD, standard deviation.
Data were missing for one patient.